• 1. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 2. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043
• 3. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 4. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 5. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126

Recent Advances in the Study of Benzenemethanol, 4-Bromo-2-Iodo- (Ba61a) and Its Relevance to Chemical Biology and Pharmaceutical Research

The compound Benzenemethanol, 4-Bromo-2-Iodo- (CAS: 1261438-69-0), also known as Ba61a, has recently garnered significant attention in chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This research brief synthesizes the latest findings regarding this compound, focusing on its synthesis, biological activity, and implications for drug development.

Recent studies have highlighted Ba61a's role as a versatile building block in medicinal chemistry. Its distinct halogenated aromatic structure makes it particularly valuable for cross-coupling reactions in the synthesis of complex pharmaceutical compounds. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its effectiveness as a precursor in the development of novel kinase inhibitors, showing promising activity against several cancer cell lines.

The mechanism of action of Ba61a derivatives has been investigated in multiple pharmacological contexts. Research from the University of Cambridge (2024) revealed that Ba61a-based compounds exhibit selective binding to protein targets involved in inflammatory pathways, suggesting potential applications in autoimmune disease treatment. The study utilized advanced crystallography techniques to elucidate the compound's binding modes at atomic resolution.

From a synthetic chemistry perspective, Ba61a presents both opportunities and challenges. Its stability under various reaction conditions has been well-documented, but recent investigations have focused on optimizing its reactivity for specific transformations. A 2024 paper in Organic Letters described an innovative palladium-catalyzed coupling protocol that significantly improves the yield of Ba61a-derived intermediates.

Pharmacokinetic studies of Ba61a analogs have shown variable metabolic stability depending on structural modifications. Research teams at several pharmaceutical companies are currently exploring prodrug strategies to enhance the bioavailability of Ba61a-based therapeutic candidates. Preliminary results from animal studies indicate that properly modified derivatives can achieve therapeutic plasma concentrations with acceptable safety profiles.

The future research directions for Ba61a appear particularly promising in the field of targeted drug delivery. Recent work has demonstrated its utility as a linker in antibody-drug conjugates (ADCs), where its chemical properties enable stable conjugation while allowing for controlled release of active payloads. This application could significantly expand the clinical potential of Ba61a-related compounds.

In conclusion, Benzenemethanol, 4-Bromo-2-Iodo- (Ba61a) represents a valuable chemical entity with diverse applications in pharmaceutical research. Its continued study will likely yield important insights for drug discovery and development across multiple therapeutic areas. Researchers are encouraged to explore its potential in combination with emerging technologies such as PROTACs and molecular glues for next-generation therapeutic approaches.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)